2011, Number 2
<< Back
Ann Hepatol 2011; 10 (2)
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C
Eslam M, Aparcero R, Romero GM
Language: English
References: 22
Page: 241-243
PDF size: 35.01 Kb.
ABSTRACT
Background & aims. Chronic hepatitis C is associated
with an increased prevalence of insulin resistance,
which might result from liver disease,
metabolic factors, or the hepatitis C virus (HCV)
itself. The effect of antiviral treatment on insulin
sensitivity is not well known. We evaluated changes
in insulin resistance and weight in patients
with hepatitis C during and after peginterferon and
ribavirin therapy.
Methods. Virahep-C was a prospective,
multi-center study of a 48-week course of
combination antiviral therapy in patients infected
with HCV genotype 1. Insulin resistance was estimated
by the homeostasis model assessment index
(HOMA2-IR) based on fasting glucose and insulin
levels.
Results. Among 341 patients, 40% had insulin
resistance (HOMA2-IR › 2.0). The presence
of insulin resistance was associated with increasing
age, body mass index, (BMI) and fibrosis stage.
Among patients with insulin resistance at the
start of the trial, median decreases in HOMA2-IR
values during treatment were 0.74 at 24 weeks and
0.89 at 48 weeks, whereas BMI decreased by 1.2
and 2.2 kg/m
2 at the same timepoints (
P ‹ 0.001
for all). At follow-up, HOMA2-IR and BMI levels
returned toward baseline values in patients that
did not respond or relapsed, but HOMA2IR values
remained significantly lower in patients with sustained
virological response (SVR) (
P ‹ 0.001), despite
increases in BMI.
Conclusions. In patients
with HCV genotype 1 infections, therapy with peginterferon
and ribavirin is associated with decreases
in body weight and insulin resistance. Among
patients with insulin resistance before treatment,
resolution of HCV infection results in sustained improvements
in the homeostasis model assessment
index, so HCV could have a direct role in the pathogenesis
of insulin resistance.
REFERENCES
Romero-Gomez M. Insulin resistance and Hepatitis C. World J Gastroenterol 2006; 12: 7075-80.
Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984-90.
Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970-7.
Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34.
Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, betacell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6.
Chehadeh W, Abdella N, Ben-Nakhi A, et al. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol 2009; 24: 42-8.
Romero-Gomez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-7.
Arab JP, Ramírez C, Arrese M. Early warning of liver disease in diabetics. Ann Hepatol 2010; 9: 307-9.
Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH; Virahep-C Study Group. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011; 140: 469-77.
Romero Gómez M. Insulin resistance and sustained virological response in hepatitis C: From bench to bedside. Liver Int 2011; 51: 1-3.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, et al. Treatment of insulin resistance with metformin in naďve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-8.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-3.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program (Letter). Diabetes Care 1998; 21: 2191–2.
Rudenski AS, Matthews DR, Levy JC, Turner RC: Understanding “insulin resistance”: both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991; 40: 908-917.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
Geloneze B, Vasques AC, Stabe CF, Pareja JC, Rosado LE, Queiroz EC, Tambascia MA. BRAMS Investigators. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol 2009; 53: 281-7.
Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB, Supiano MA. Limitation of the homeostasis model assessment to predict insulin resistance and beta-cell dysfunction in older people. J Clin Endocrinol Metab 2006; 91: 629-34.
Safar FH, Mojiminiyi OA, Al-Rumaih HM, Diejomaoh MF. Computational methods are significant determinants of the associations and definitions of insulin resistance using the homeostasis model assessment in women of reproductive age. Clin Chem 2011; 57: 279-85.
Mojiminiyi OA, Abdella NA. Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. Clin Chem Lab Med 2010; 48: 1629-34.
Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut 2011; (in press).